Description
BACE1 enzyme levels are elevated in AD brains despite no known pathogenic mutations in the BACE1 gene. The regulatory mechanisms driving this elevation and their causal role in disease progression remain unexplained.
Gap type: unexplained_observation Source paper: Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. (2017, Expert opinion on investigational drugs, PMID:28817311)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:42.524566+00:00”, “resolution_summary”: “Resolved by hypothesis h-a6e77292: SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via Autophagosome-Lysosome Fusion Dysfunction. Supporting evidence includes debate sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731.”, “match_counts”: {“hypothesis_matches”: 2, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-a6e77292”, “title”: “SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via Autophagosome-Lysosome Fusion Dysfunction”, “score”: 0.223, “reason”: “19 token overlaps; entity overlap: bace1”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-083737-59771b32”, “target_gene”: “SGMS1, BECN1”, “target_pathway”: “Autophagy / beclin-1”, “disease”: “neurodegeneration”, “composite_score”: 0.734, “confidence_score”: 0.72, “status”: “promoted”, “pubmed_evidence_ids”: [“23827971”, “23977395”, “28028177”, “30243987”, “N/A”]}, {“id”: “hyp-SDA-2026-04-12-20260411-082446-2c1c9e2d-2”, “title”: “Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology”, “score”: 0.222, “reason”: “20 token overlaps; entity overlap: bace1”, “analysis_id”: “SDA-2026-04-12-20260411-082446-2c1c9e2d”, “target_gene”: “CHRNA7 (α7 nicotinic receptor), BACE1”, “target_pathway”: “Cholinergic signaling pathway”, “disease”: null, “composite_score”: 0.785, “confidence_score”: 0.55, “status”: “debated”, “pubmed_evidence_ids”: [“20600777”, “20943921”, “21921156”, “23201341”, “23324234”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.521, “reason”: “9 token overlaps; entity overlap: bace1, pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5”, “title”: “The abstract identifies APOE4 association with increased TDP-43 pathology but the mechanistic link is unexplained. This connection could reveal novel therapeutic targets since APOE4 is the strongest genetic risk factor for AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.396, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “title”: “The abstract shows TYROBP deficiency is neuroprotective despite being required for TREM2, CD33, and CR3 function - receptors associated with AD risk. This counterintuitive finding challenges current understanding of how these immune receptors contribute to AD pathogenesis.\n\nGap type: contradiction\nSource paper: Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology. (None, None, PMID:28612290)”, “score”: 0.378, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “quality_score”: 0.56, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-183548-043c7918”, “title”: “The authors evaluate several ALS-associated mutations in OPTN’s leucine-zipper domain but don’t fully explain how these mutations mechanistically lead to disease pathogenesis. Understanding this link is critical for developing targeted ALS therapies.\n\nGap type: unexplained_observation\nSource paper: Molecular Basis of the Recognition of the Active Rab8a by Optineurin. (2024, Journal of molecular biology, PMID:39374890)”, “score”: 0.37, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-183548-043c7918”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-06-gap-pubmed-20260406-041428-4c4414ad_task_9aae8fc5”, “title”: “The study shows stress granules are dynamic and reversible assemblies, but in neurodegeneration they become pathological and persistent. The molecular mechanisms governing this transition from physiological to pathological states remain unexplained, yet understanding this could reveal therapeutic targets.\n\nGap type: unexplained_observation\nSource paper: G3BP1 Is a Tunable Switch that Triggers Phase Separation to Assemble Stress Granules. (2020, Cell, PMID:32302571)”, “score”: 0.37, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-06-gap-pubmed-20260406-041428-4c4414ad”, “quality_score”: 0.843, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}